A review finds that semaglutide, a GLP-1 receptor agonist approved for diabetes, significantly reduced alcohol consumption and relapse in rat studies, suggesting potential for treating alcohol use disorder — especially in overweight patients.
Significant reduction in alcohol consumption and relapse in ratsSemaglutide, already approved for diabetes and obesity, showed promising anti-alcohol effects in preclinical studies, particularly for overweight individuals with alcohol use disorder.
What the researchers found
Preclinical studies demonstrate that semaglutide significantly reduces alcohol consumption and relapse of alcohol addiction in rats. The GLP-1 system, described as a gut-brain peptide pathway, is implicated in the neurobiology of addictive behaviors, making the GLP-1 receptor a promising therapeutic target for alcohol use disorder.
The review notes that semaglutide may be particularly effective for overweight patients with AUD, given its dual effects on metabolism and brain reward pathways. However, safety concerns include gallbladder disease and complications from delayed gastric emptying, necessitating careful evaluation before broader clinical use.
Why it matters
Alcohol use disorder affects millions of people worldwide, yet approved medications are few and underutilized. Repurposing semaglutide — an already approved, well-studied peptide drug — could provide a new treatment option much faster than developing a drug from scratch. The connection between gut-brain peptide signaling and addiction also opens a new frontier in understanding why people develop substance use disorders.
How the study worked
This is a review article that compiled and evaluated preclinical (animal) and clinical findings on the GLP-1 system's role in addiction and semaglutide's potential for treating alcohol use disorder. The authors also assessed the safety profile of semaglutide to inform its potential application beyond diabetes.
What this study cannot tell us
The key evidence for alcohol reduction comes from rat studies, which may not fully predict human outcomes. No large-scale human clinical trials specifically testing semaglutide for AUD are reported in this review. The safety concerns (gallbladder disease, gastroparesis) could limit use in some patients. The review also notes the heterogeneity and complexity of AUD, suggesting semaglutide may not work for all patient subgroups.
How to read the evidence
This is a narrative review primarily drawing on preclinical animal data. While the biological rationale is compelling and the drug is already approved for other conditions, the evidence for AUD treatment specifically remains at the animal study stage, which is relatively early in the evidence hierarchy.
When this study was published
Published in 2025, this is a very current review that captures the latest wave of interest in GLP-1 receptor agonists for addiction. Human clinical trials testing this application are likely underway or forthcoming.
The bigger picture
This review is part of a rapidly growing body of evidence linking GLP-1 receptor agonists to reduced addictive behaviors — not just for alcohol, but potentially for nicotine, opioids, and other substances. If human clinical trials confirm the animal findings, semaglutide could become one of the most significant addiction treatment breakthroughs in decades, leveraging its existing safety and manufacturing infrastructure.
Questions still open
- Will randomized controlled trials in humans confirm that semaglutide reduces alcohol consumption and prevents relapse?
- Is the anti-addiction effect of semaglutide primarily driven by its brain effects, its metabolic effects, or a combination of both?
- Could oral semaglutide be as effective as injectable forms for treating alcohol use disorder?
Common questions
How might semaglutide help with alcohol addiction?
Can someone currently take semaglutide for alcohol addiction?
Read the original research
Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder.
Pharmacopsychiatry, 58(6), 255-262
Citation
Liu, Tingting; Shi, Fuqiang; Guo, Zhihua; Li, Hongwu; Qin, Di. (2025). Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder.. Pharmacopsychiatry, 58(6), 255-262. https://doi.org/10.1055/a-2550-6470